Investors in Immunology

Malin invests in and supports highly innovative life sciences companies developing cutting-edge science and technology to deliver transformative outcomes for patients and create significant value for shareholders. Headquartered in Ireland and listed on the Euronext Growth Market of Euronext Dublin, Malin aims to generate substantial returns for shareholders through long-term capital and strategic support to its investee companies. Focused on therapeutic areas like oncology, immunology, and genetic diseases, Malin prioritizes business integrity, collaboration with talented individuals, and the development of groundbreaking therapies where current treatments are inadequate.

UCB Ventures is a €150 million strategic corporate venture fund. UCB is a global biopharmaceutical company focused on neurology and immunology disorders, driven by innovative science to enhance patient lives worldwide. We work closely and forge strong connections with patients, caregivers, health care professionals and other stakeholders who know the challenges of these diseases and where the unmet needs are found all too well.